Advertisements


Roche says entrectinib shrank tumours harbouring NTRK, ROS1 or ALK gene fusions

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallMay 16th, 2019

Entrectinib shrank tumors in people with NTRK fusion-positive solid tumors

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallOct 21st, 2018

Tender offer deadline in $4.3B Roche-Spark deal pushed back for a fifth time.

Roche has extended, yet again, its tender offer to Spark Therapeutics in connection with the proposed $4.3 billion purchase of the Philadelphia gene therapy pioneer. For those keeping track, this is the fifth time the companies announced a new deadl.....»»

Category: topSource: bizjournalsJul 31st, 2019

Roche, Spark extend $4.3 billion takeover again, this time to September 3

Roche and Spark Therapeutics announced another extension of the Swiss drugmaker's $4.3 billion takeover offer for the U.S. gene therapy specialist as regulatory reviews in the United States and Britain continue......»»

Category: topSource: reutersJul 31st, 2019

Roche, Spark push back takeover deadline in $4.3 billion deal

Swiss drugmaker Roche has agreed to extend the takeover deadline in its $4.3 billion bid for U.S. gene therapy specialist Spark Therapeutics , adding it remains "fully committed" to the transaction and expects it to close this year......»»

Category: topSource: reutersJul 8th, 2019

Roche Extends Deadline For Spark Acquisition As US, UK Regulators Seek Additional Information

Swiss drug giant Roche Holdings AG Basel ADR (OTC: RHHBY) has announced another delay in its proposed takeover of the gene therapy biotech Spark Therapeutics Inc (NASDAQ: ONCE). read more.....»»

Category: blogSource: benzingaJun 10th, 2019

$4.8 billion deal for gene therapy pioneer Spark Therapeutics delayed once more

The finish line for their proposed $4.8 billion deal is proving to be quite elusive for Roche and Spark Therapeutics. The companies announced Monday they have have each received a request for additional information and documentary material from the F.....»»

Category: topSource: bizjournalsJun 10th, 2019

Roche"s $4.3 billion Spark bid delayed again amid U.S., UK scrutiny

Swiss drugmaker Roche's $4.3 billion takeover of U.S. gene therapy specialist Spark Therapeutics has been pushed back again, possibly beyond the first half, as regulators continue to scrutinize the deal for its effect on competition......»»

Category: topSource: reutersJun 10th, 2019

Roche launches first in vitro diagnostic IHC test for ROS1 protein in cancers

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallMay 28th, 2019

Genentech says entrectinib shrank tumors in Phase I/II study

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallMay 15th, 2019

Roche says $4.3 billion Spark offer still on track for June completion

Roche Holding said its effort to expand in gene therapy via the $4.3 billion takeover of Spark Therapeutics remained on track despite failing to get enough votes to clinch the deal and as U.S. regulators continued scrutinizing it......»»

Category: topSource: reutersApr 3rd, 2019

Roche extends Spark offer after getting only 29 percent

Roche Holding has extended until May 2 its $4.3 billion offer for U.S. gene therapy specialist Spark Therapeutics, the Swiss drugmaker said after getting only 29.4 percent of Spark's shares in a tender originally due to end on Wednesday......»»

Category: topSource: reutersApr 3rd, 2019

Gene Therapy M&A Has Shares Skyrocketing -- Could This Company Be Next?

Roche and Biogen are spending big bucks on gene therapy biotech stocks......»»

Category: topSource: foxnewsMar 8th, 2019

Roche takes on Loxo, Bayer in gene-defined cancer class - Reuters

ReutersRoche takes on Loxo, Bayer in gene-defined cancer classReutersMUNICH (Reuters) - Roche'.....»»

Category: topSource: googlenewsOct 21st, 2018

Roche"s (RHHBY) BLA for Lymphoma Drug Gets Priority Review

The FDA accepts Roche's (RHHBY) BLA for polatuzumab vedotin and NDAs for entrectinib, an.....»»

Category: dealsSource: nytFeb 19th, 2019

Roche bids $4.8B for Spark and its gene therapy

Roche Holding AG will buy Spark Therapeutics Inc. for $4.8 billion, a deal that will give the Swiss drugmaker one of the first-ever therapies to treat, and potentially cure, a disease by providing a fix for a patient’s defective genes......»»

Category: topSource: moneycentralFeb 25th, 2019

Roche Bids $4.3 Billion for U.S.-Based Gene Therapy Specialist Spark

Purchasing Philadelphia-based Spark will help Roche to compete with Basel-based neighbor Novartis AG in developing the new area of medicine .....»»

Category: europeSource: fortuneFeb 25th, 2019

Roche may spark another bull run for gene therapy names, says Credit Suisse

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallFeb 25th, 2019

Roche Bids $4.8 Billion for U.S.-Based Gene Therapy Specialist Spark

Purchasing Philadelphia-based Spark will help Roche to compete with Basel-based neighbor Novartis AG in developing the new area of medicine .....»»

Category: europeSource: fortuneFeb 25th, 2019

Roche bets $4.3 billionon Spark in gene therapy move

Roche Holding AG is to buy U.S.-based Spark Therapeutics in a $4.3 billion deal that will give the Swiss drugmaker a foothold in gene therapy. Ciara Lee reports......»»

Category: topSource: moneycentralFeb 25th, 2019

Sell-Side Picks Top Gene Therapy Takeout Candidates Following Spark Therapeutics Deal

Roche Holdings AG Basel ADR (OTC: RHHBY)'s announcement regarding an agreement to acquire gene therapy company Spark Therapeutics Inc (NASDAQ: Latest Ratings fo.....»»

Category: blogSource: benzingaFeb 25th, 2019